Navigation Links
Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
Date:2/22/2013

ROCKVILLE, Md., Feb. 22, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its flupirtine sublicensee, Meda AB (Meda), has received a green light from the Food and Drug Administration (FDA) to conduct a Phase II proof of concept study for the treatment of fibromyalgia as reported in Meda's 2012 year-end report. Meda has announced that the randomized, double-blind, placebo and active-controlled study of patients with fibromyalgia will be conducted at 25 clinics in the U.S.

In May 2010, the Company entered into an agreement with Sweden-based Meda granting exclusive sublicense to all of its patents and pending patents covering the use of flupirtine for fibromyalgia in the U.S., Canada and Japan. Meda assumed all future development costs for the commercialization of flupirtine for fibromyalgia. Synthetic Biologics received an upfront payment and is entitled to future milestone payments, plus royalties.

"We are pleased to share Meda's update on the status of its clinical development program of flupirtine for fibromyalgia," stated Jeffrey Riley , Chief Executive Officer at Synthetic Biologics. "We believe Meda's experience with flupirtine outside of the U.S. will help bring this potential new class of treatment to the millions of people that suffer from fibromyalgia in the U.S."

About Fibromyalgia and Flupirtine

Fibromyalgia is a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body, accompanied by severe fatigue, insomnia and mood symptoms. Fibromyalgia affects an estimated 3-6% of the population worldwide, including an estimated 10 million patients in the U.S. There are presently three products approved for this indication in
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
2. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
3. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
4. The Use of New Replikins Synthetic Vaccines to Prevent Pandemics to be Presented at Influenza Congress Nov. 12 in Washington DC
5. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
6. Synthetic Biologics Reports Second Quarter 2012 Financial Results
7. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
8. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
9. Employers Becoming Savvier About Biologics and Specialty Drugs
10. Pinnacle Biologics beantragt Zulassung neuer Indikationen in Deutschland und Frankreich
11. Pinnacle Biologics dépose une nouvelle indication pharmaceutique en Allemagne et en France
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (NYSE: RMD ) today announced results for its ... 2014.  Revenue for the quarter was $415.2 million, flat compared ... decrease on a constant currency basis). Net income was $87.7 ... ended June 30, 2013. Diluted earnings per share for the ... the quarter ended June 30, 2013.  The ...
(Date:7/31/2014)... Therapeutics (Nasdaq: NKTR ) today reported its financial ... Cash and investments in marketable securities at June ... at March 31, 2014."The second half of 2014 will be ... significant milestones for a number of our late-stage clinical programs," ... Nektar. "The first of these is the potential US and ...
(Date:7/31/2014)... Mass. , July 31, 2014 /PRNewswire/ ... funding changes brought about by the Affordable ... reimbursement and prescribing of pharmaceutical therapies. The ... cover beneficiaries through new regulations and expanded ... occurring in the health exchanges—state-based marketplaces set ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... 5, 2010 Sequenom, Inc. (Nasdaq: SQNM ... overview of the company at the following conferences in ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) Lazard Capital ... St. Regis, New York, NY Presentation date: Tuesday ...
... 2010 EnVivo Pharmaceuticals today announced it has discovered ... a novel mechanism not previously seen in the scientific ... to enhance cognition. By acting as a ... possible for smaller amounts of naturally occurring ACh, typically ...
Cached Medicine Technology:Sequenom to Present at Two Financial Conferences in November 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 3
(Date:8/1/2014)... According to Forrester Research, more than 90 percent of ... of information, and thanks to the launching of DCInsurers Agent ... resources on insurance specifically for the state of Colorado can ... step in the growth of our business,” Doug King, owner/agent ... Insurance Resources office. “We recognize that the web is how ...
(Date:8/1/2014)... KY (PRWEB) August 01, 2014 Frontier ... Health Resources and Services Administration’s Advanced Education Nursing ... and will provide direct support to 280 students over ... the AENT Program is to increase the number of ... providers and/or nursing faculty to address the nurse faculty ...
(Date:8/1/2014)... and doctors at the Institute of Bioengineering and ... Cancer Centre Singapore (NCCS) have co-developed the first ... survival outcomes in kidney cancer patients. This breakthrough ... the world,s top urology journal. , According ... "By combining our expertise in molecular diagnostics and ...
(Date:8/1/2014)... St. Christopher's Hospital for Children announced that they ... with Ed Begley Jr, airing later this year 2014, ... St. Christopher's Hospital for Children offers a wide range ... 21 years of age. With over 220 pediatric specialists, ... autism and childhood obesity. , “St. Christopher’s is ...
(Date:8/1/2014)... Utah (PRWEB) August 01, 2014 This ... MonaVie, who completes its 500th week of paying commissions ... the company was founded in January 2005 total $1,405,954,677.06. ... throughout the world. The company pays commissions in 18 ... ILS, JPY, MYR, MXN, NZD, PLN, USD, SGD, KRW, ...
Breaking Medicine News(10 mins):Health News:DCInsurers Agent Doug King Launches a New Website 2Health News:DCInsurers Agent Doug King Launches a New Website 3Health News:Frontier Nursing University Receives $700,000 in Scholarships for Advanced Practice Nursing and Midwifery Students 2Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2
... between Elsevier and Diabetes India. The partnership would be ... Diabetes Research & Metabolic Syndrome in June 2006. // ... relationship between diabetes and metabolic syndrome with special reference ... centered approach in treatment of the disorder. ,Diabetes India ...
... breakthrough, scientists have successfully converted human embryonic stem ... future, replacement cartilage could be grown for transplantation ... problems, including sports injuries, new cartilage for people ... reconstructive surgery. , ,The research, to be ...
... scientists have developed a natural or rather biological pacemaker ... heart muscle cells. The newly developed pacemaker can fire ... the heart in a more physiological way., ,Two ... rise to the heart’s normal rhythm by stimulating other ...
... drugs is on the rise in England, accounting for more ... department each year. , ,The findings are based on ... a hospital in South West England. The doctor in charge ... for treatment with special reference to illegal drug abuse., ...
... previous claims new evidence shows the high fat, low carb ... Atkins (or simply the Atkins' diet) could damage the heart., ... and low // carbohydrates directly affected the heart's ability to ... and colleagues from the Cardiac Metabolism Research Group of Oxford ...
... know that heart disease is ranked as the first ... a new, simple test called dobutamine stress echocardiography that ... , ,The study has been conducted among a ... The study participants underwent a certain type of stress ...
Cached Medicine News:Health News:Partnership Between Diabetes India And Elsevier Announced 2Health News:Another Potential Of Stem Cells Discovered: Used For Growing Cartilage 2Health News:Novel Biological Pacemaker Under Construction for Weak Hearts 2Health News:Heart damage a consequence of Atkins’ Die 2Health News:A Simple Test To Detect Heart Disease In Women Can Be Lifesaving 2
The 15D provides high magnification along with an optimized working distance from the cornea. With its 4.11x magnification it is also well suited for disc and macular observation....
... iQ200 Automated Urine Microscopy Analyzer (iQ200) ... (APR) software to classify urine particles ... results. The iQ200 eliminates most technologist ... particle images by automating specimen preparation, ...
... The iQ®200 Sprint Automated Urinalysis System ... fully automated system that performs complete urinalyses ... away. Designed for high volume laboratories or ... The iQ200 Sprint has a processing speed ...
StarClose Clip Applier, (includes), Clip Applier, 6F Exchange Sheath, 6F Dilator, 0.038 50 cm J-Tip Guide Wire ...
Medicine Products: